Kolexia
Lequeu Hélène Oncologie hémato.
Lequeu Hélène
Oncologie hémato.
Hôpital Lyon Sud
Pierre-Bénite, France
33 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome B diffus à grandes cellules Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Lymphome malin non hodgkinien Myélome multiple Hémopathies

Collaborateurs

Voir plus
Ferrant Emmanuelle
Ferrant Emmanuelle
Hôpital Lyon Sud, Pierre-Bénite, France
Danielou-Lazareth Anne
Danielou-Lazareth Anne
Hôpital Lyon Sud, Pierre-Bénite, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France
Safar Violaine
Safar Violaine
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Celgene
1 collaboration(s)
Dernière en 2020
GSK
1 collaboration(s)
Dernière en 2022
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Skeletal Muscle Index, As a Measure of Muscle Mass, Is a Significant Prognostic Factor for Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood advances   06 mars 2023
Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital
Annual Meeting Abstracts 2022   15 novembre 2022
Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019
Annual Meeting Abstracts 2022   15 novembre 2022
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Leukemia & lymphoma   31 octobre 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Clinical nuclear medicine   08 juillet 2021
Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma
Blood   05 novembre 2020
Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
Blood   05 novembre 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
American journal of hematology   25 août 2020
Des lymphocytes supérieurs à 5 000/mm3 plus de 3 mois.
La Revue du praticien   20 novembre 2019